Last reviewed · How we verify
Placebo hypogonadal
This is a placebo control used in clinical trials to assess the efficacy of hypogonadal treatments through comparison against an inert substance.
This is a placebo control used in clinical trials to assess the efficacy of hypogonadal treatments through comparison against an inert substance. Used for Hypogonadism (control arm in clinical trials).
At a glance
| Generic name | Placebo hypogonadal |
|---|---|
| Sponsor | Medical University of Graz |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
A placebo has no active pharmacological mechanism; it serves as a control arm in clinical studies of hypogonadism therapies. By comparing active treatment outcomes to placebo responses, researchers can isolate the true therapeutic effect of investigational hypogonadal interventions and account for natural disease progression and psychological effects.
Approved indications
- Hypogonadism (control arm in clinical trials)
Common side effects
Key clinical trials
- A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea (PHASE2)
- Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone (PHASE2)
- A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (PHASE4)
- Testosterone and Alendronate in Hypogonadal Men (PHASE2)
- Natesto Testosterone Nasal Gel for Hypogonadal Men (PHASE4)
- Anastrozole Administration in Elderly Hypogonadal Men (PHASE2)
- Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80 (PHASE2)
- Testosterone for Peripheral Vascular Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo hypogonadal CI brief — competitive landscape report
- Placebo hypogonadal updates RSS · CI watch RSS
- Medical University of Graz portfolio CI